IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients

Michael A. Pulsipher, Chris Carlson, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, Ilan Kirsch, Julie M. Gastier-Foster, Michael J Borowitz, Cindy Desmarais, David Williamson, Michael Kalos, Stephan A. Grupp

Research output: Contribution to journalArticle

Abstract

Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)-MRD better identifies pre-and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children's Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P <.0001), especially in the MRD negative cohort (relapse, 0%vs16%; P=.02; 2-year overall survival, 96% vs 77%;P=.003).Post-HCT NGS-MRD detection was better at predicting relapse than MFC-MRD (P

Original languageEnglish (US)
Pages (from-to)3501-3508
Number of pages8
JournalBlood
Volume125
Issue number22
DOIs
StatePublished - May 28 2015

Fingerprint

Immunoglobulin Heavy Chains
Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Flow cytometry
Cell Transplantation
Flow Cytometry
Recurrence
Oncology
Survival
DNA sequences
Joining
B-Lymphocytes
Cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Pulsipher, M. A., Carlson, C., Langholz, B., Wall, D. A., Schultz, K. R., Bunin, N., ... Grupp, S. A. (2015). IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients. Blood, 125(22), 3501-3508. https://doi.org/10.1182/blood-2014-12-615757

IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients. / Pulsipher, Michael A.; Carlson, Chris; Langholz, Bryan; Wall, Donna A.; Schultz, Kirk R.; Bunin, Nancy; Kirsch, Ilan; Gastier-Foster, Julie M.; Borowitz, Michael J; Desmarais, Cindy; Williamson, David; Kalos, Michael; Grupp, Stephan A.

In: Blood, Vol. 125, No. 22, 28.05.2015, p. 3501-3508.

Research output: Contribution to journalArticle

Pulsipher, MA, Carlson, C, Langholz, B, Wall, DA, Schultz, KR, Bunin, N, Kirsch, I, Gastier-Foster, JM, Borowitz, MJ, Desmarais, C, Williamson, D, Kalos, M & Grupp, SA 2015, 'IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients', Blood, vol. 125, no. 22, pp. 3501-3508. https://doi.org/10.1182/blood-2014-12-615757
Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N et al. IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients. Blood. 2015 May 28;125(22):3501-3508. https://doi.org/10.1182/blood-2014-12-615757
Pulsipher, Michael A. ; Carlson, Chris ; Langholz, Bryan ; Wall, Donna A. ; Schultz, Kirk R. ; Bunin, Nancy ; Kirsch, Ilan ; Gastier-Foster, Julie M. ; Borowitz, Michael J ; Desmarais, Cindy ; Williamson, David ; Kalos, Michael ; Grupp, Stephan A. / IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients. In: Blood. 2015 ; Vol. 125, No. 22. pp. 3501-3508.
@article{77c13c8d11de4a2db6eab05e3e1f1146,
title = "IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients",
abstract = "Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)-MRD better identifies pre-and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children's Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P <.0001), especially in the MRD negative cohort (relapse, 0{\%}vs16{\%}; P=.02; 2-year overall survival, 96{\%} vs 77{\%};P=.003).Post-HCT NGS-MRD detection was better at predicting relapse than MFC-MRD (P",
author = "Pulsipher, {Michael A.} and Chris Carlson and Bryan Langholz and Wall, {Donna A.} and Schultz, {Kirk R.} and Nancy Bunin and Ilan Kirsch and Gastier-Foster, {Julie M.} and Borowitz, {Michael J} and Cindy Desmarais and David Williamson and Michael Kalos and Grupp, {Stephan A.}",
year = "2015",
month = "5",
day = "28",
doi = "10.1182/blood-2014-12-615757",
language = "English (US)",
volume = "125",
pages = "3501--3508",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients

AU - Pulsipher, Michael A.

AU - Carlson, Chris

AU - Langholz, Bryan

AU - Wall, Donna A.

AU - Schultz, Kirk R.

AU - Bunin, Nancy

AU - Kirsch, Ilan

AU - Gastier-Foster, Julie M.

AU - Borowitz, Michael J

AU - Desmarais, Cindy

AU - Williamson, David

AU - Kalos, Michael

AU - Grupp, Stephan A.

PY - 2015/5/28

Y1 - 2015/5/28

N2 - Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)-MRD better identifies pre-and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children's Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P <.0001), especially in the MRD negative cohort (relapse, 0%vs16%; P=.02; 2-year overall survival, 96% vs 77%;P=.003).Post-HCT NGS-MRD detection was better at predicting relapse than MFC-MRD (P

AB - Positive detection of minimal residual disease (MRD) by multichannel flow cytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)-MRD better identifies pre-and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children's Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P <.0001), especially in the MRD negative cohort (relapse, 0%vs16%; P=.02; 2-year overall survival, 96% vs 77%;P=.003).Post-HCT NGS-MRD detection was better at predicting relapse than MFC-MRD (P

UR - http://www.scopus.com/inward/record.url?scp=84930960200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930960200&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-12-615757

DO - 10.1182/blood-2014-12-615757

M3 - Article

C2 - 25862561

AN - SCOPUS:84930960200

VL - 125

SP - 3501

EP - 3508

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -